STRATA CRITICAL MED INC C/WTS 07/05/2026 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 49.3 M

Revenue: As of FY2025 Q3, the actual value is USD 49.3 M.

EPS: As of FY2025 Q3, the actual value is USD 0.7.

EBIT: As of FY2025 Q3, the actual value is USD -6.749 M.

Interest Income
- Three Months Ended September 30, 2025: $1,127 thousand
- Three Months Ended September 30, 2024: $1,764 thousand
- Nine Months Ended September 30, 2025: $3,603 thousand
- Nine Months Ended September 30, 2024: $5,624 thousand
Change in Fair Value of Warrant Liabilities
- Three Months Ended September 30, 2025: $33 thousand
- Three Months Ended September 30, 2024: -$299 thousand
- Nine Months Ended September 30, 2025: $2,862 thousand
- Nine Months Ended September 30, 2024: $2,266 thousand
Realized Loss from Sales of Short-Term Investments
- Three Months Ended September 30, 2025: -$5,195 thousand
- Nine Months Ended September 30, 2025: -$5,195 thousand

Continuing Operations
- Three Months Ended September 30, 2025: -$0.12
- Three Months Ended September 30, 2024: -$0.07
- Nine Months Ended September 30, 2025: -$0.18
- Nine Months Ended September 30, 2024: -$0.11
Discontinued Operations
- Three Months Ended September 30, 2025: $0.81
- Three Months Ended September 30, 2024: $0.05
- Nine Months Ended September 30, 2025: $0.80
- Nine Months Ended September 30, 2024: -$0.11
Total Basic and Diluted Earnings (Loss) Per Share
- Three Months Ended September 30, 2025: $0.70
- Three Months Ended September 30, 2024: -$0.03
- Nine Months Ended September 30, 2025: $0.62
- Nine Months Ended September 30, 2024: -$0.23

Net Cash Used in Operating Activities
- Nine Months Ended September 30, 2025: -$40,607 thousand
- Nine Months Ended September 30, 2024: -$767 thousand
Net Cash Provided by / (Used in) Investing Activities
- Nine Months Ended September 30, 2025: $51,485 thousand
- Nine Months Ended September 30, 2024: -$4,992 thousand
Net Cash Used in Financing Activities
- Nine Months Ended September 30, 2025: -$7,170 thousand
- Nine Months Ended September 30, 2024: -$1,885 thousand
Effect of Foreign Exchange Rate Changes on Cash Balances
- Nine Months Ended September 30, 2025: -$339 thousand
- Nine Months Ended September 30, 2024: $29 thousand
Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash
- Nine Months Ended September 30, 2025: $3,369 thousand
- Nine Months Ended September 30, 2024: -$7,615 thousand

Core Business Focus: The company aims to leverage its expertise and resources to provide other medical and logistics services to a broader customer base, closely aligning its goals with those of all participants in the transplant ecosystem, including transplant centers, regulators, Organ Procurement Organizations (OPOs), and other service providers.
Non-Core Business: The company completed the sale of its Passenger business to Joby Aero, Inc. on August 29, 2025, and the acquisition of Keystone Perfusion Services, LLC on September 16, 2025. The company expects to realize various benefits from these transactions, including cost efficiencies and accretive benefits, and aims to successfully integrate Keystone and retain its key employees and clients.
Priority: The company anticipates that it has sufficient funds to meet its current operational needs for at least the next 12 months from the date of filing this Quarterly Report. The company may seek external sources of financing in the future to take advantage of market opportunities.